Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies
Background: Two approaches for detecting anti-prothrombin antibodies have been described. The first detects antibodies against prothrombin alone and the second, phos-phatidylserine-dependent antiprothrombin antibodies. The latter more often correlate with clinical manifestations of antiphospholipid...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Walter de Gruyter ; 2011 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Reproduktion: |
Walter de Gruyter Online Zeitschriften |
|---|---|
| Übergeordnetes Werk: |
Enthalten in: Clinical chemistry and laboratory medicine - Berlin [u.a.] : De Gruyter, 1998, 49(2011), 6 vom: 17. Mai, Seite 1011-1018 |
| Übergeordnetes Werk: |
volume:49 ; year:2011 ; number:6 ; day:17 ; month:05 ; pages:1011-1018 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1515/CCLM.2011.162 |
|---|
| Katalog-ID: |
NLEJ246734035 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ246734035 | ||
| 003 | DE-627 | ||
| 005 | 20230506145606.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220814s2011 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1515/CCLM.2011.162 |2 doi | |
| 028 | 5 | 2 | |a artikel_Grundlieferung.pp |
| 035 | |a (DE-627)NLEJ246734035 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 245 | 1 | 0 | |a Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies |
| 264 | 1 | |b Walter de Gruyter |c 2011 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: Two approaches for detecting anti-prothrombin antibodies have been described. The first detects antibodies against prothrombin alone and the second, phos-phatidylserine-dependent antiprothrombin antibodies. The latter more often correlate with clinical manifestations of antiphospholipid syndrome and with lupus anticoagulant activity. Methods: In order to increase the capacity of antibody binding, we modified the previously described phosphatidylser-ine-dependent antiprothrombin ELISA and determined their avidity. We examined 203 patients with systemic autoimmune diseases and 222 blood donors. Results: Our modification resulted in a greater intensity of antibody binding to prothrombin on phosphatidylserine-coated plate surfaces compared to the previously described method. By changing ELISA conditions, we were able to detect with one assay the two, presumably different, populations of antiprothrombin antibodies. Diagnostic specificities of both ELISAs for antiphospholipid syndrome were similar (92.5% vs. 93.1%), while the sensitivity of the modified phosphatidylserine-dependent antiprothrombin ELISA was significantly higher than the anti-prothrombin alone ELISA (59% vs. 25%). Low avidity antiprothrombin antibodies were only detected in the modified phosphatidylserine-dependent antiprothrombin ELISA. Four percent of patients with positive phosphatidylserine-dependent antiprothrombin antibodies, showing clinical manifestations of antiphospholipid syndrome, were negative for all other antiphospholipid antibodies. The risk for antiphospholipid syndrome increased with the number of antiphospholipid antibody positivity. Conclusions: We conclude that antibodies detected with a modified phosphatidylserine-dependent antiprothrombin ELISA could improve the diagnosis of antiphospholipid syndrome by offering additional information on the risk for thrombosis, especially in patients negative for other antiphospholipid antibodies. | ||
| 533 | |f Walter de Gruyter Online Zeitschriften | ||
| 650 | 4 | |a antiphospholipid antibody | |
| 650 | 4 | |a antiphospholipid syndrome | |
| 650 | 4 | |a antiprothrombin antibodies | |
| 650 | 4 | |a enzyme immunoassay | |
| 650 | 4 | |a phosphatidylserine-dependent antiprothrombin antibodies | |
| 700 | 1 | |a Žigon, Polona |4 oth | |
| 700 | 1 | |a Ambrožič, Aleš |4 oth | |
| 700 | 1 | |a Čučnik, Saša |4 oth | |
| 700 | 1 | |a Kveder, Tanja |4 oth | |
| 700 | 1 | |a Rozman, Blaž |4 oth | |
| 700 | 1 | |a Božič, Borut |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d Berlin [u.a.] : De Gruyter, 1998 |g 49(2011), 6 vom: 17. Mai, Seite 1011-1018 |w (DE-627)NLEJ248235222 |w (DE-600)1492732-9 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2011 |g number:6 |g day:17 |g month:05 |g pages:1011-1018 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1515/CCLM.2011.162 |z Deutschlandweit zugänglich |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DGR | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2011 |e 6 |b 17 |c 05 |h 1011-1018 |g 8 | ||
| matchkey_str |
article:14374331:2011----::oiidhshtdleieeednattrmieianbeietfctooptetngtvfrteatpopoiia |
|---|---|
| hierarchy_sort_str |
2011 |
| publishDate |
2011 |
| allfields |
10.1515/CCLM.2011.162 doi artikel_Grundlieferung.pp (DE-627)NLEJ246734035 DE-627 ger DE-627 rakwb Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies Walter de Gruyter 2011 8 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Two approaches for detecting anti-prothrombin antibodies have been described. The first detects antibodies against prothrombin alone and the second, phos-phatidylserine-dependent antiprothrombin antibodies. The latter more often correlate with clinical manifestations of antiphospholipid syndrome and with lupus anticoagulant activity. Methods: In order to increase the capacity of antibody binding, we modified the previously described phosphatidylser-ine-dependent antiprothrombin ELISA and determined their avidity. We examined 203 patients with systemic autoimmune diseases and 222 blood donors. Results: Our modification resulted in a greater intensity of antibody binding to prothrombin on phosphatidylserine-coated plate surfaces compared to the previously described method. By changing ELISA conditions, we were able to detect with one assay the two, presumably different, populations of antiprothrombin antibodies. Diagnostic specificities of both ELISAs for antiphospholipid syndrome were similar (92.5% vs. 93.1%), while the sensitivity of the modified phosphatidylserine-dependent antiprothrombin ELISA was significantly higher than the anti-prothrombin alone ELISA (59% vs. 25%). Low avidity antiprothrombin antibodies were only detected in the modified phosphatidylserine-dependent antiprothrombin ELISA. Four percent of patients with positive phosphatidylserine-dependent antiprothrombin antibodies, showing clinical manifestations of antiphospholipid syndrome, were negative for all other antiphospholipid antibodies. The risk for antiphospholipid syndrome increased with the number of antiphospholipid antibody positivity. Conclusions: We conclude that antibodies detected with a modified phosphatidylserine-dependent antiprothrombin ELISA could improve the diagnosis of antiphospholipid syndrome by offering additional information on the risk for thrombosis, especially in patients negative for other antiphospholipid antibodies. Walter de Gruyter Online Zeitschriften antiphospholipid antibody antiphospholipid syndrome antiprothrombin antibodies enzyme immunoassay phosphatidylserine-dependent antiprothrombin antibodies Žigon, Polona oth Ambrožič, Aleš oth Čučnik, Saša oth Kveder, Tanja oth Rozman, Blaž oth Božič, Borut oth Enthalten in Clinical chemistry and laboratory medicine Berlin [u.a.] : De Gruyter, 1998 49(2011), 6 vom: 17. Mai, Seite 1011-1018 (DE-627)NLEJ248235222 (DE-600)1492732-9 1437-4331 nnns volume:49 year:2011 number:6 day:17 month:05 pages:1011-1018 extent:8 https://doi.org/10.1515/CCLM.2011.162 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 49 2011 6 17 05 1011-1018 8 |
| spelling |
10.1515/CCLM.2011.162 doi artikel_Grundlieferung.pp (DE-627)NLEJ246734035 DE-627 ger DE-627 rakwb Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies Walter de Gruyter 2011 8 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Two approaches for detecting anti-prothrombin antibodies have been described. The first detects antibodies against prothrombin alone and the second, phos-phatidylserine-dependent antiprothrombin antibodies. The latter more often correlate with clinical manifestations of antiphospholipid syndrome and with lupus anticoagulant activity. Methods: In order to increase the capacity of antibody binding, we modified the previously described phosphatidylser-ine-dependent antiprothrombin ELISA and determined their avidity. We examined 203 patients with systemic autoimmune diseases and 222 blood donors. Results: Our modification resulted in a greater intensity of antibody binding to prothrombin on phosphatidylserine-coated plate surfaces compared to the previously described method. By changing ELISA conditions, we were able to detect with one assay the two, presumably different, populations of antiprothrombin antibodies. Diagnostic specificities of both ELISAs for antiphospholipid syndrome were similar (92.5% vs. 93.1%), while the sensitivity of the modified phosphatidylserine-dependent antiprothrombin ELISA was significantly higher than the anti-prothrombin alone ELISA (59% vs. 25%). Low avidity antiprothrombin antibodies were only detected in the modified phosphatidylserine-dependent antiprothrombin ELISA. Four percent of patients with positive phosphatidylserine-dependent antiprothrombin antibodies, showing clinical manifestations of antiphospholipid syndrome, were negative for all other antiphospholipid antibodies. The risk for antiphospholipid syndrome increased with the number of antiphospholipid antibody positivity. Conclusions: We conclude that antibodies detected with a modified phosphatidylserine-dependent antiprothrombin ELISA could improve the diagnosis of antiphospholipid syndrome by offering additional information on the risk for thrombosis, especially in patients negative for other antiphospholipid antibodies. Walter de Gruyter Online Zeitschriften antiphospholipid antibody antiphospholipid syndrome antiprothrombin antibodies enzyme immunoassay phosphatidylserine-dependent antiprothrombin antibodies Žigon, Polona oth Ambrožič, Aleš oth Čučnik, Saša oth Kveder, Tanja oth Rozman, Blaž oth Božič, Borut oth Enthalten in Clinical chemistry and laboratory medicine Berlin [u.a.] : De Gruyter, 1998 49(2011), 6 vom: 17. Mai, Seite 1011-1018 (DE-627)NLEJ248235222 (DE-600)1492732-9 1437-4331 nnns volume:49 year:2011 number:6 day:17 month:05 pages:1011-1018 extent:8 https://doi.org/10.1515/CCLM.2011.162 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 49 2011 6 17 05 1011-1018 8 |
| allfields_unstemmed |
10.1515/CCLM.2011.162 doi artikel_Grundlieferung.pp (DE-627)NLEJ246734035 DE-627 ger DE-627 rakwb Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies Walter de Gruyter 2011 8 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Two approaches for detecting anti-prothrombin antibodies have been described. The first detects antibodies against prothrombin alone and the second, phos-phatidylserine-dependent antiprothrombin antibodies. The latter more often correlate with clinical manifestations of antiphospholipid syndrome and with lupus anticoagulant activity. Methods: In order to increase the capacity of antibody binding, we modified the previously described phosphatidylser-ine-dependent antiprothrombin ELISA and determined their avidity. We examined 203 patients with systemic autoimmune diseases and 222 blood donors. Results: Our modification resulted in a greater intensity of antibody binding to prothrombin on phosphatidylserine-coated plate surfaces compared to the previously described method. By changing ELISA conditions, we were able to detect with one assay the two, presumably different, populations of antiprothrombin antibodies. Diagnostic specificities of both ELISAs for antiphospholipid syndrome were similar (92.5% vs. 93.1%), while the sensitivity of the modified phosphatidylserine-dependent antiprothrombin ELISA was significantly higher than the anti-prothrombin alone ELISA (59% vs. 25%). Low avidity antiprothrombin antibodies were only detected in the modified phosphatidylserine-dependent antiprothrombin ELISA. Four percent of patients with positive phosphatidylserine-dependent antiprothrombin antibodies, showing clinical manifestations of antiphospholipid syndrome, were negative for all other antiphospholipid antibodies. The risk for antiphospholipid syndrome increased with the number of antiphospholipid antibody positivity. Conclusions: We conclude that antibodies detected with a modified phosphatidylserine-dependent antiprothrombin ELISA could improve the diagnosis of antiphospholipid syndrome by offering additional information on the risk for thrombosis, especially in patients negative for other antiphospholipid antibodies. Walter de Gruyter Online Zeitschriften antiphospholipid antibody antiphospholipid syndrome antiprothrombin antibodies enzyme immunoassay phosphatidylserine-dependent antiprothrombin antibodies Žigon, Polona oth Ambrožič, Aleš oth Čučnik, Saša oth Kveder, Tanja oth Rozman, Blaž oth Božič, Borut oth Enthalten in Clinical chemistry and laboratory medicine Berlin [u.a.] : De Gruyter, 1998 49(2011), 6 vom: 17. Mai, Seite 1011-1018 (DE-627)NLEJ248235222 (DE-600)1492732-9 1437-4331 nnns volume:49 year:2011 number:6 day:17 month:05 pages:1011-1018 extent:8 https://doi.org/10.1515/CCLM.2011.162 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 49 2011 6 17 05 1011-1018 8 |
| allfieldsGer |
10.1515/CCLM.2011.162 doi artikel_Grundlieferung.pp (DE-627)NLEJ246734035 DE-627 ger DE-627 rakwb Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies Walter de Gruyter 2011 8 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Two approaches for detecting anti-prothrombin antibodies have been described. The first detects antibodies against prothrombin alone and the second, phos-phatidylserine-dependent antiprothrombin antibodies. The latter more often correlate with clinical manifestations of antiphospholipid syndrome and with lupus anticoagulant activity. Methods: In order to increase the capacity of antibody binding, we modified the previously described phosphatidylser-ine-dependent antiprothrombin ELISA and determined their avidity. We examined 203 patients with systemic autoimmune diseases and 222 blood donors. Results: Our modification resulted in a greater intensity of antibody binding to prothrombin on phosphatidylserine-coated plate surfaces compared to the previously described method. By changing ELISA conditions, we were able to detect with one assay the two, presumably different, populations of antiprothrombin antibodies. Diagnostic specificities of both ELISAs for antiphospholipid syndrome were similar (92.5% vs. 93.1%), while the sensitivity of the modified phosphatidylserine-dependent antiprothrombin ELISA was significantly higher than the anti-prothrombin alone ELISA (59% vs. 25%). Low avidity antiprothrombin antibodies were only detected in the modified phosphatidylserine-dependent antiprothrombin ELISA. Four percent of patients with positive phosphatidylserine-dependent antiprothrombin antibodies, showing clinical manifestations of antiphospholipid syndrome, were negative for all other antiphospholipid antibodies. The risk for antiphospholipid syndrome increased with the number of antiphospholipid antibody positivity. Conclusions: We conclude that antibodies detected with a modified phosphatidylserine-dependent antiprothrombin ELISA could improve the diagnosis of antiphospholipid syndrome by offering additional information on the risk for thrombosis, especially in patients negative for other antiphospholipid antibodies. Walter de Gruyter Online Zeitschriften antiphospholipid antibody antiphospholipid syndrome antiprothrombin antibodies enzyme immunoassay phosphatidylserine-dependent antiprothrombin antibodies Žigon, Polona oth Ambrožič, Aleš oth Čučnik, Saša oth Kveder, Tanja oth Rozman, Blaž oth Božič, Borut oth Enthalten in Clinical chemistry and laboratory medicine Berlin [u.a.] : De Gruyter, 1998 49(2011), 6 vom: 17. Mai, Seite 1011-1018 (DE-627)NLEJ248235222 (DE-600)1492732-9 1437-4331 nnns volume:49 year:2011 number:6 day:17 month:05 pages:1011-1018 extent:8 https://doi.org/10.1515/CCLM.2011.162 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 49 2011 6 17 05 1011-1018 8 |
| allfieldsSound |
10.1515/CCLM.2011.162 doi artikel_Grundlieferung.pp (DE-627)NLEJ246734035 DE-627 ger DE-627 rakwb Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies Walter de Gruyter 2011 8 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Two approaches for detecting anti-prothrombin antibodies have been described. The first detects antibodies against prothrombin alone and the second, phos-phatidylserine-dependent antiprothrombin antibodies. The latter more often correlate with clinical manifestations of antiphospholipid syndrome and with lupus anticoagulant activity. Methods: In order to increase the capacity of antibody binding, we modified the previously described phosphatidylser-ine-dependent antiprothrombin ELISA and determined their avidity. We examined 203 patients with systemic autoimmune diseases and 222 blood donors. Results: Our modification resulted in a greater intensity of antibody binding to prothrombin on phosphatidylserine-coated plate surfaces compared to the previously described method. By changing ELISA conditions, we were able to detect with one assay the two, presumably different, populations of antiprothrombin antibodies. Diagnostic specificities of both ELISAs for antiphospholipid syndrome were similar (92.5% vs. 93.1%), while the sensitivity of the modified phosphatidylserine-dependent antiprothrombin ELISA was significantly higher than the anti-prothrombin alone ELISA (59% vs. 25%). Low avidity antiprothrombin antibodies were only detected in the modified phosphatidylserine-dependent antiprothrombin ELISA. Four percent of patients with positive phosphatidylserine-dependent antiprothrombin antibodies, showing clinical manifestations of antiphospholipid syndrome, were negative for all other antiphospholipid antibodies. The risk for antiphospholipid syndrome increased with the number of antiphospholipid antibody positivity. Conclusions: We conclude that antibodies detected with a modified phosphatidylserine-dependent antiprothrombin ELISA could improve the diagnosis of antiphospholipid syndrome by offering additional information on the risk for thrombosis, especially in patients negative for other antiphospholipid antibodies. Walter de Gruyter Online Zeitschriften antiphospholipid antibody antiphospholipid syndrome antiprothrombin antibodies enzyme immunoassay phosphatidylserine-dependent antiprothrombin antibodies Žigon, Polona oth Ambrožič, Aleš oth Čučnik, Saša oth Kveder, Tanja oth Rozman, Blaž oth Božič, Borut oth Enthalten in Clinical chemistry and laboratory medicine Berlin [u.a.] : De Gruyter, 1998 49(2011), 6 vom: 17. Mai, Seite 1011-1018 (DE-627)NLEJ248235222 (DE-600)1492732-9 1437-4331 nnns volume:49 year:2011 number:6 day:17 month:05 pages:1011-1018 extent:8 https://doi.org/10.1515/CCLM.2011.162 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 49 2011 6 17 05 1011-1018 8 |
| source |
Enthalten in Clinical chemistry and laboratory medicine 49(2011), 6 vom: 17. Mai, Seite 1011-1018 volume:49 year:2011 number:6 day:17 month:05 pages:1011-1018 extent:8 |
| sourceStr |
Enthalten in Clinical chemistry and laboratory medicine 49(2011), 6 vom: 17. Mai, Seite 1011-1018 volume:49 year:2011 number:6 day:17 month:05 pages:1011-1018 extent:8 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
antiphospholipid antibody antiphospholipid syndrome antiprothrombin antibodies enzyme immunoassay phosphatidylserine-dependent antiprothrombin antibodies |
| isfreeaccess_bool |
false |
| container_title |
Clinical chemistry and laboratory medicine |
| authorswithroles_txt_mv |
Žigon, Polona @@oth@@ Ambrožič, Aleš @@oth@@ Čučnik, Saša @@oth@@ Kveder, Tanja @@oth@@ Rozman, Blaž @@oth@@ Božič, Borut @@oth@@ |
| publishDateDaySort_date |
2011-05-17T00:00:00Z |
| hierarchy_top_id |
NLEJ248235222 |
| id |
NLEJ246734035 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ246734035</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506145606.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220814s2011 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/CCLM.2011.162</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">artikel_Grundlieferung.pp</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ246734035</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="b">Walter de Gruyter</subfield><subfield code="c">2011</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Two approaches for detecting anti-prothrombin antibodies have been described. The first detects antibodies against prothrombin alone and the second, phos-phatidylserine-dependent antiprothrombin antibodies. The latter more often correlate with clinical manifestations of antiphospholipid syndrome and with lupus anticoagulant activity. Methods: In order to increase the capacity of antibody binding, we modified the previously described phosphatidylser-ine-dependent antiprothrombin ELISA and determined their avidity. We examined 203 patients with systemic autoimmune diseases and 222 blood donors. Results: Our modification resulted in a greater intensity of antibody binding to prothrombin on phosphatidylserine-coated plate surfaces compared to the previously described method. By changing ELISA conditions, we were able to detect with one assay the two, presumably different, populations of antiprothrombin antibodies. Diagnostic specificities of both ELISAs for antiphospholipid syndrome were similar (92.5% vs. 93.1%), while the sensitivity of the modified phosphatidylserine-dependent antiprothrombin ELISA was significantly higher than the anti-prothrombin alone ELISA (59% vs. 25%). Low avidity antiprothrombin antibodies were only detected in the modified phosphatidylserine-dependent antiprothrombin ELISA. Four percent of patients with positive phosphatidylserine-dependent antiprothrombin antibodies, showing clinical manifestations of antiphospholipid syndrome, were negative for all other antiphospholipid antibodies. The risk for antiphospholipid syndrome increased with the number of antiphospholipid antibody positivity. Conclusions: We conclude that antibodies detected with a modified phosphatidylserine-dependent antiprothrombin ELISA could improve the diagnosis of antiphospholipid syndrome by offering additional information on the risk for thrombosis, especially in patients negative for other antiphospholipid antibodies.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Walter de Gruyter Online Zeitschriften</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antiphospholipid antibody</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antiphospholipid syndrome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antiprothrombin antibodies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">enzyme immunoassay</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phosphatidylserine-dependent antiprothrombin antibodies</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Žigon, Polona</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ambrožič, Aleš</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Čučnik, Saša</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kveder, Tanja</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rozman, Blaž</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Božič, Borut</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical chemistry and laboratory medicine</subfield><subfield code="d">Berlin [u.a.] : De Gruyter, 1998</subfield><subfield code="g">49(2011), 6 vom: 17. Mai, Seite 1011-1018</subfield><subfield code="w">(DE-627)NLEJ248235222</subfield><subfield code="w">(DE-600)1492732-9</subfield><subfield code="x">1437-4331</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:49</subfield><subfield code="g">year:2011</subfield><subfield code="g">number:6</subfield><subfield code="g">day:17</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:1011-1018</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/CCLM.2011.162</subfield><subfield code="z">Deutschlandweit zugänglich</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DGR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">49</subfield><subfield code="j">2011</subfield><subfield code="e">6</subfield><subfield code="b">17</subfield><subfield code="c">05</subfield><subfield code="h">1011-1018</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
| series2 |
Walter de Gruyter Online Zeitschriften |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ248235222 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1437-4331 |
| topic_title |
Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies antiphospholipid antibody antiphospholipid syndrome antiprothrombin antibodies enzyme immunoassay phosphatidylserine-dependent antiprothrombin antibodies |
| publisher |
Walter de Gruyter |
| publisherStr |
Walter de Gruyter |
| topic |
misc antiphospholipid antibody misc antiphospholipid syndrome misc antiprothrombin antibodies misc enzyme immunoassay misc phosphatidylserine-dependent antiprothrombin antibodies |
| spellingShingle |
misc antiphospholipid antibody misc antiphospholipid syndrome misc antiprothrombin antibodies misc enzyme immunoassay misc phosphatidylserine-dependent antiprothrombin antibodies Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies |
| topic_unstemmed |
misc antiphospholipid antibody misc antiphospholipid syndrome misc antiprothrombin antibodies misc enzyme immunoassay misc phosphatidylserine-dependent antiprothrombin antibodies |
| topic_browse |
misc antiphospholipid antibody misc antiphospholipid syndrome misc antiprothrombin antibodies misc enzyme immunoassay misc phosphatidylserine-dependent antiprothrombin antibodies |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| author2_variant |
p ž pž a a aa s č sč t k tk b r br b b bb |
| hierarchy_parent_title |
Clinical chemistry and laboratory medicine |
| hierarchy_parent_id |
NLEJ248235222 |
| hierarchy_top_title |
Clinical chemistry and laboratory medicine |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ248235222 (DE-600)1492732-9 |
| title |
Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies |
| ctrlnum |
(DE-627)NLEJ246734035 |
| title_full |
Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies |
| journal |
Clinical chemistry and laboratory medicine |
| journalStr |
Clinical chemistry and laboratory medicine |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2011 |
| contenttype_str_mv |
txt |
| container_start_page |
1011 |
| container_volume |
49 |
| physical |
8 |
| format_se |
Elektronische Aufsätze |
| doi_str_mv |
10.1515/CCLM.2011.162 |
| title_sort |
modified phosphatidylserine-dependent antithrombin elisa enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies |
| title_auth |
Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies |
| abstract |
Background: Two approaches for detecting anti-prothrombin antibodies have been described. The first detects antibodies against prothrombin alone and the second, phos-phatidylserine-dependent antiprothrombin antibodies. The latter more often correlate with clinical manifestations of antiphospholipid syndrome and with lupus anticoagulant activity. Methods: In order to increase the capacity of antibody binding, we modified the previously described phosphatidylser-ine-dependent antiprothrombin ELISA and determined their avidity. We examined 203 patients with systemic autoimmune diseases and 222 blood donors. Results: Our modification resulted in a greater intensity of antibody binding to prothrombin on phosphatidylserine-coated plate surfaces compared to the previously described method. By changing ELISA conditions, we were able to detect with one assay the two, presumably different, populations of antiprothrombin antibodies. Diagnostic specificities of both ELISAs for antiphospholipid syndrome were similar (92.5% vs. 93.1%), while the sensitivity of the modified phosphatidylserine-dependent antiprothrombin ELISA was significantly higher than the anti-prothrombin alone ELISA (59% vs. 25%). Low avidity antiprothrombin antibodies were only detected in the modified phosphatidylserine-dependent antiprothrombin ELISA. Four percent of patients with positive phosphatidylserine-dependent antiprothrombin antibodies, showing clinical manifestations of antiphospholipid syndrome, were negative for all other antiphospholipid antibodies. The risk for antiphospholipid syndrome increased with the number of antiphospholipid antibody positivity. Conclusions: We conclude that antibodies detected with a modified phosphatidylserine-dependent antiprothrombin ELISA could improve the diagnosis of antiphospholipid syndrome by offering additional information on the risk for thrombosis, especially in patients negative for other antiphospholipid antibodies. |
| abstractGer |
Background: Two approaches for detecting anti-prothrombin antibodies have been described. The first detects antibodies against prothrombin alone and the second, phos-phatidylserine-dependent antiprothrombin antibodies. The latter more often correlate with clinical manifestations of antiphospholipid syndrome and with lupus anticoagulant activity. Methods: In order to increase the capacity of antibody binding, we modified the previously described phosphatidylser-ine-dependent antiprothrombin ELISA and determined their avidity. We examined 203 patients with systemic autoimmune diseases and 222 blood donors. Results: Our modification resulted in a greater intensity of antibody binding to prothrombin on phosphatidylserine-coated plate surfaces compared to the previously described method. By changing ELISA conditions, we were able to detect with one assay the two, presumably different, populations of antiprothrombin antibodies. Diagnostic specificities of both ELISAs for antiphospholipid syndrome were similar (92.5% vs. 93.1%), while the sensitivity of the modified phosphatidylserine-dependent antiprothrombin ELISA was significantly higher than the anti-prothrombin alone ELISA (59% vs. 25%). Low avidity antiprothrombin antibodies were only detected in the modified phosphatidylserine-dependent antiprothrombin ELISA. Four percent of patients with positive phosphatidylserine-dependent antiprothrombin antibodies, showing clinical manifestations of antiphospholipid syndrome, were negative for all other antiphospholipid antibodies. The risk for antiphospholipid syndrome increased with the number of antiphospholipid antibody positivity. Conclusions: We conclude that antibodies detected with a modified phosphatidylserine-dependent antiprothrombin ELISA could improve the diagnosis of antiphospholipid syndrome by offering additional information on the risk for thrombosis, especially in patients negative for other antiphospholipid antibodies. |
| abstract_unstemmed |
Background: Two approaches for detecting anti-prothrombin antibodies have been described. The first detects antibodies against prothrombin alone and the second, phos-phatidylserine-dependent antiprothrombin antibodies. The latter more often correlate with clinical manifestations of antiphospholipid syndrome and with lupus anticoagulant activity. Methods: In order to increase the capacity of antibody binding, we modified the previously described phosphatidylser-ine-dependent antiprothrombin ELISA and determined their avidity. We examined 203 patients with systemic autoimmune diseases and 222 blood donors. Results: Our modification resulted in a greater intensity of antibody binding to prothrombin on phosphatidylserine-coated plate surfaces compared to the previously described method. By changing ELISA conditions, we were able to detect with one assay the two, presumably different, populations of antiprothrombin antibodies. Diagnostic specificities of both ELISAs for antiphospholipid syndrome were similar (92.5% vs. 93.1%), while the sensitivity of the modified phosphatidylserine-dependent antiprothrombin ELISA was significantly higher than the anti-prothrombin alone ELISA (59% vs. 25%). Low avidity antiprothrombin antibodies were only detected in the modified phosphatidylserine-dependent antiprothrombin ELISA. Four percent of patients with positive phosphatidylserine-dependent antiprothrombin antibodies, showing clinical manifestations of antiphospholipid syndrome, were negative for all other antiphospholipid antibodies. The risk for antiphospholipid syndrome increased with the number of antiphospholipid antibody positivity. Conclusions: We conclude that antibodies detected with a modified phosphatidylserine-dependent antiprothrombin ELISA could improve the diagnosis of antiphospholipid syndrome by offering additional information on the risk for thrombosis, especially in patients negative for other antiphospholipid antibodies. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE |
| container_issue |
6 |
| title_short |
Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies |
| url |
https://doi.org/10.1515/CCLM.2011.162 |
| remote_bool |
true |
| author2 |
Žigon, Polona Ambrožič, Aleš Čučnik, Saša Kveder, Tanja Rozman, Blaž Božič, Borut |
| author2Str |
Žigon, Polona Ambrožič, Aleš Čučnik, Saša Kveder, Tanja Rozman, Blaž Božič, Borut |
| ppnlink |
NLEJ248235222 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| doi_str |
10.1515/CCLM.2011.162 |
| up_date |
2024-07-06T09:13:34.495Z |
| _version_ |
1803820428948406272 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ246734035</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506145606.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220814s2011 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/CCLM.2011.162</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">artikel_Grundlieferung.pp</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ246734035</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="b">Walter de Gruyter</subfield><subfield code="c">2011</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Two approaches for detecting anti-prothrombin antibodies have been described. The first detects antibodies against prothrombin alone and the second, phos-phatidylserine-dependent antiprothrombin antibodies. The latter more often correlate with clinical manifestations of antiphospholipid syndrome and with lupus anticoagulant activity. Methods: In order to increase the capacity of antibody binding, we modified the previously described phosphatidylser-ine-dependent antiprothrombin ELISA and determined their avidity. We examined 203 patients with systemic autoimmune diseases and 222 blood donors. Results: Our modification resulted in a greater intensity of antibody binding to prothrombin on phosphatidylserine-coated plate surfaces compared to the previously described method. By changing ELISA conditions, we were able to detect with one assay the two, presumably different, populations of antiprothrombin antibodies. Diagnostic specificities of both ELISAs for antiphospholipid syndrome were similar (92.5% vs. 93.1%), while the sensitivity of the modified phosphatidylserine-dependent antiprothrombin ELISA was significantly higher than the anti-prothrombin alone ELISA (59% vs. 25%). Low avidity antiprothrombin antibodies were only detected in the modified phosphatidylserine-dependent antiprothrombin ELISA. Four percent of patients with positive phosphatidylserine-dependent antiprothrombin antibodies, showing clinical manifestations of antiphospholipid syndrome, were negative for all other antiphospholipid antibodies. The risk for antiphospholipid syndrome increased with the number of antiphospholipid antibody positivity. Conclusions: We conclude that antibodies detected with a modified phosphatidylserine-dependent antiprothrombin ELISA could improve the diagnosis of antiphospholipid syndrome by offering additional information on the risk for thrombosis, especially in patients negative for other antiphospholipid antibodies.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Walter de Gruyter Online Zeitschriften</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antiphospholipid antibody</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antiphospholipid syndrome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antiprothrombin antibodies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">enzyme immunoassay</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phosphatidylserine-dependent antiprothrombin antibodies</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Žigon, Polona</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ambrožič, Aleš</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Čučnik, Saša</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kveder, Tanja</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rozman, Blaž</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Božič, Borut</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical chemistry and laboratory medicine</subfield><subfield code="d">Berlin [u.a.] : De Gruyter, 1998</subfield><subfield code="g">49(2011), 6 vom: 17. Mai, Seite 1011-1018</subfield><subfield code="w">(DE-627)NLEJ248235222</subfield><subfield code="w">(DE-600)1492732-9</subfield><subfield code="x">1437-4331</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:49</subfield><subfield code="g">year:2011</subfield><subfield code="g">number:6</subfield><subfield code="g">day:17</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:1011-1018</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/CCLM.2011.162</subfield><subfield code="z">Deutschlandweit zugänglich</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DGR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">49</subfield><subfield code="j">2011</subfield><subfield code="e">6</subfield><subfield code="b">17</subfield><subfield code="c">05</subfield><subfield code="h">1011-1018</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
| score |
7.401636 |